Skip to main content
Just-released results from international trials indicate a potential vaccine, designed to protect against nine HPV strains, might be the next step in cervical cancer protection. In the pivotal Phase III efficacy study, the investigational 9-valent HPV vaccine prevented approximately 97% of cervical, vaginal, and vulvar pre-cancers caused by HPV types 31, 33, 45, 52, and 58.

Potential HPV vaccine shows promise.

January 1, 2014

Just-released results from international trials indicate a potential vaccine, designed to protect against nine HPV strains, might be the next step in cervical cancer protection. In the pivotal Phase III efficacy study, the investigational 9-valent HPV vaccine prevented approximately 97% of cervical, vaginal, and vulvar pre-cancers caused by HPV types 31, 33, 45, 52, and 58.
Article Limit Reached

You have reached your article limit for the month. Subscribe now to access this article plus other member-only content.

  • Award-winning Medical Content
  • Latest Advances & Development in Medicine
  • Unbiased Content
View Subscription Details

Already have an account? Log in